|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Latest insights into the effects of Helicobacter pylori infection on gastric carcinogenesis显示文摘看起来是在 Helicobacter pylori (H pylori ) 和胃的癌症之间的强壮的协会。我们在胃的致癌作用上关于 H pylori 感染的效果考察了最近的证据,分类进传染病学,胃的粘膜变化的动力学, DNA 损坏,毒力因素,主人因素,和胃的恶意的来源。通过在对源于 H pylori 紧张之间的差别的毒力因素的研究取得的可观的进步,例如 cagA 确实,以及进主人因素,例如基因多型性,包括胃的癌症, H 联系 pylori 的疾病的一个多样的系列把自己正在借给说明。当发展研究上的胃的恶意的潜在的来源与兴趣尚待分晓,建议骨头髓的 Houghton 等推进的新奇假设的影响导出干细胞(BMDC ) 。进一步作为胃的癌症的可行预防在对 H pylori 根除,以及进胃的致癌作用的机制的研究进行,是急切地被等候当前的年并且在以外。 | Kazunari Murakami Masaaki Kodama Toshio Fujioka | 2006 | World Journal of Gastroenterology2006，12，17： | 20 |
| 2 | Helicobacter pylori-infected animal models are extremely suitable for the investigation of gastric carcinogenesis显示文摘Although various animal models have been developed to clarify gastric carcinogenesis, apparent mechanism of gastric cancer was not clarified in recent years. Since the recognition of the pathogenicity of Helicobacter pylori (Hpylori), several animal models with Hpylori infection have been developed to confirm the association between Hpylori and gastric cancer. Nonhuman primate and rodent models were suitable for this study. Japanese monkey model revealed atrophic gastritis and p53mutation after long-term infection of Hpylori. Mongolian gerbil model showed the development of gastric carcinoma with H pylori infection alone, as well as with combination of chemical carcinogens, such as N-methylN-nitrosourea and N-methyl-N-nitro-N'-nitrosoguanidine.The histopathological changes of these animal models after Hpylori inoculation are closely similar to those in human beings with Hpylori infection. Eradication therapy attenuated the development of gastric cancer in Hpyloriinfected Mongolian gerbil. Although several features of animal models differ from those seen in human beings,these experimental models provide a starting point for further studies to clarify the mechanism of gastric carcinogenesis as a result of Hpylori infection and assist the planning of eradication therapy to prevent gastric carcinoma. | Masaaki Kodama Kazunari Murakami Ryugo Sato Tadayoshi Okimoto Akira Nishizono Toshio Fujioka | 2005 | World Journal of Gastroenterology2005，11，45： | 19 |
| 3 | Expression of mutant type-p53 products in H pylori-associated chronic gastritis显示文摘AIM:To investigate the mutation of p 53 immuno-histochemically in non-tumorous gastric mucosa with H pylori infection before and after H pylori eradication therapy.METHODS:53 subjects(36 male,17 female,mean age ± SEM,57.1 ± 12.1)undergoing endoscopic examination were included in this study.42 of 53 patients were H pylori-positive,and 11 were H pylori-negative.All H pylori-positive patients had successful eradication therapy.Biopsy specimens were taken from five points of the stomach,as recommended by the updated Sydney system.Immunohistochemical studies were performed by using primary antibodies against p53(DO-7 and PAb240).RESULTS:p53(DO-7 and PAb240)immunoreactivity was shown in the neck region of the gastric pits,however,quite a few cells were found to be immunopositive for p 53(PAb240)in the H pylori-infected gastric mucosa.The proportion of patients immunopositive for p 53(PAb240)was significantly reduced 6 mo after eradication [28/42(66.7%)to 6/42(14.3%)](P < 0.05),while the biopsies taken from H pylori-negative patients showed no immunoreactivity for p53(PAb240).p53(PAb240)-positive patients were divided into two groups by the number of positive cells detected:one with more than six positive cells per 10 gastric pits(group A,n = 12),and the other with less than five positive cells per 10 gastric pits(group B,n = 30).Atrophy scores in group A were significant higher than those in group B at the greater curvature of the antrum(group A:2.00 ± 0.14 vs group B:1.40 ± 0.15,P = 0.012),the lesser curvature of the corpus(group A:2.00 ± 0.21 vs group B:1.07 ± 0.23,P = 0.017),and the greater curvature of the corpus(group A:1.20 ± 0.30vs group B:0.47 ± 0.21,P = 0.031).Group A showed significant higher intestinal metaplasia scores than group B only at the lesser curvature of the antrum(group A:2.10 ± 0.41 vs group B:1.12 ± 0.29,P = 0.035).CONCLUSION:H pylori-associated chronic gastritis expressed the mutant-type p53,which was significantly associated with more severe atrophic and metaplastic changes.H pylori eradication led to a significant reduction in the expression of the mutant-type p53.It is considered that H pylori-infected chronic gastritis is associated with a genetic instability that leads to gastric carcinogenesis,and H pylori eradication may prevent gastric cancer. | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Koichiro Watanabe Toshio Fujioka | 2007 | World Journal of Gastroenterology2007，13，10： | 13 |
| 4 | Aspirin-induced small bowel injuries and the preventive effect of rebamipide显示文摘AIM:To evaluate the influence of taking low-dose aspirin for 4 wk on small intestinal complications and to examine the preventive effect of rebamipide.METHODS:This study was conducted as a single-center,randomized,double-blind,cross-over,placebo-controlled study.Eleven healthy male subjects were enrolled.Each subject underwent video capsule endos-copy after 1 and 4 wk of taking aspirin and omepra-zole,along with either rebamipide or placebo therapy.The primary endpoint was to evaluate small bowel damage in healthy subjects before and after taking low-dose aspirin for 4 wk.RESULTS:The number of subjects with mucosal breaks(defined as multiple erosions and/or ulcers)were 1 at 1 wk and 1 at 4 wk on the jejunum,and 6 at 1 wk(P = 0.0061)and 7 at 4 wk on the ileum(P =0.0019).Rebamipide significantly prevented mucosal breaks on the ileum compared with the placebo group(P = 0.0173 at 1 wk and P = 0.0266 at 4 wk).CONCLUSION:Longer-term,low-dose aspirin adminis-tration induced damage in the small bowel.Rebamipide prevented this damage,and may be a candidate drug for treating aspirin-induced small bowel complications. | Kazuhiro Mizukami Kazunari Murakami Takashi Abe Kunimitsu Inoue Masahiro Uchida Tadayoshi Okimoto Masaaki Kodama Toshio Fujioka | 2011 | World Journal of Gastroenterology2011，17，46： | 8 |
| 5 | Extremely high prevalence of Helicobacter pylori infection in Bhutan显示文摘AIM: To revealed the prevalence of Helicobacter pylori (H. pylori ) infection in the Bhutanese population. METHODS: We recruited a total of 372 volunteers (214 females and 158 males; mean age of 39.6 ± 14.9 years) from three Bhutanese cities (Thimphu, Punaka, and Wangdue). The status of H. pylori infection was determined based on five different tests: the rapid urease test (CLO test), culture, histology, immunohistochemistry (IHC), and serum anti H. pylori -antibody. RESULTS: The serological test showed a significantly higher positive rate compared with the CLO test, culture, histology and IHC (P < 0.001, P < 0.001, P=0.01, and P=0.01, respectively). When the subjects were considered to be H. pylori positive in the case of at least one test showing a positive result, the overall prevalence of H. pylori infection in Bhutan was 73.4%. The prevalence of H. pylori infection significantly decreased with age (P < 0.01). The prevalence of H. pylori infection was lower in Thimphu than in Punakha and Wangdue (P=0.001 and 0.06, respectively). The prevalence of H. pylori infection was significantly higher in patients with peptic ulcers than in those with gastritis (91.4% vs 71.3%, P=0.003). CONCLUSION: The high incidence of gastric cancer in Bhutan may be attributed to the high prevalence of H. pylori infection. | Ratha-korn Vilaichone Varocha Mahachai Seiji Shiota Tomohisa Uchida Thawee Ratanachu-ek Lotay Tshering Nguyen Lam Tung Toshio Fujioka Masatsugu Moriyama Yoshio Yamaoka | 2013 | World Journal of Gastroenterology2013，19，18： | 8 |
| 6 | Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test显示文摘AIM: To investigate the effects of proton pump inhibitor (PPI) treatment on stool antigen test using the TestMate pylori enzyme immunoassay. METHODS: This study assessed 28 patients [16 men and 12 women; mean age (63.1 ± 5.9) years; range, 25-84 years] who underwent stool antigen test and urea breath test (UBT) before and after PPI administration. RESULTS: Using the UBT as the standard, the sensitivity, specif icity and agreement of the stool antigen test in all 28 patients were 95.2%, 71.4%, and 89.3%, respectively, before PPI administration, and 88.9%, 90.9%, and 89.3%, respectively, after PPI treatment. Mean UBT values were 23.98% ± 5.33% before and 16.19% ± 4.75% after PPI treatment and, in 15 patients treated for ≥ 4 wk, were signif icantly lower after than before 4 wk of PPI treatment (12.58% ± 4.49% vs 24.53% ± 8.53%, P = 0.048). The mean optical density (A450/630) ratios on the stool antigen test were 1.16 ± 0.20 before and 1.17 ± 0.24 after PPI treatment (P = 0.989), and were 1.02 ± 0.26 and 0.69 ± 0.28, respectively, in the group treated for > 4 wk (P = 0.099). | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Yoshihiro Fukuda Tadashi Shimoyama Masumi Okuda Chieko Kato Intetsu Kobayashi Toshio Fujioka | 2012 | World Journal of Gastroenterology2012，18，1： | 7 |
| 7 | Antibiotics resistance rate of Helicobacter pylori in Bhutan显示文摘AIM:To survey the antibiotic resistance pattern of Helicobacter pylori(H.pylori)strains isolated from Bhutanese population.METHODS:We isolated 111 H.pylori strains from the gastric mucosa of H.pylori-infected patients in Bhutan in 2010.The Epsilometer test was used to determine the minimum inhibitory concentrations(MICs)of amoxicillin(AMX),clarithromycin(CLR),metronidazole(MNZ),levofloxacin(LVX),ciprofloxacin(CIP),and tetracycline(TET).RESULTS:Nineteen of the isolated H.pylori strains were susceptible to all antibiotics tested.The isolated strains showed the highest rate of antibiotic resistance to MNZ(92/111,82.9%).Among the 92 MNZresistant strains,74 strains(80.4%)showed high-level resistance(MIC≥256 g/mL).Three strains were resistance to LVX(2.7%).These strains were also resistance to CIP.None of the strains showed resistance to CLR,AMX and TET.CONCLUSION:CLR-based triple therapy is a more effective treatment approach over MNZ-based triple therapy for H.pylori infection in Bhutan. | Ratha-korn Vilaichone Yoshio Yamaoka Seiji Shiota Thawee Ratanachu-ek Lotay Tshering Tomohisa Uchida Toshio Fujioka Varocha Mahachai | 2013 | World Journal of Gastroenterology2013，19，33： | 6 |
| 8 | Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy显示文摘 | Hisanori Abe Kazunari Murakami Shunzo Satoh Ryugo Sato Masaaki Kodama Tsuyoshi Arita Toshio Fujioka | 2005 | Journal of Gastroenterology2005，，6： | 4 |
| 9 | Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication显示文摘 | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Masahiro Uchida Takashi Abe Seiji Shiota Yoshifumi Nakagawa Kazuhiro Mizukami Toshio Fujioka | 2012 | Journal of Gastroenterology2012，，4： | 4 |
| 10 | The Incidence of Primary Antibiotic Resistance of Helicobacter pylori in Vietnam显示文摘 | Tran T. Binh Seiji Shiota Lam T. Nguyen Dung D.Q. Ho Hai H. Hoang Long Ta Dung T. Trinh Toshio Fujioka Yoshio Yamaoka | 2013 | Journal of Clinical Gastroenterology2013，，3： | 2 |
| 11 | Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy显示文摘 | Hisanori Abe Kazunari Murakami Shunzo Satoh Ryugo Sato Masaaki Kodama Tsuyoshi Arita Toshio Fujioka | 2005 | Journal of Gastroenterology2005，，6： | 1 |
| 12 | Blood Pressure and Hypertension Are Associated With 7 Loci in the Japanese Population显示文摘 | Fumihiko Takeuchi Masato Isono Tomohiro Katsuya Ken Yamamoto Mitsuhiro Yokota Takao Sugiyama Toru Nabika Akihiro Fujioka Keizo Ohnaka Hiroyuki Asano Yukio Yamori Shuhei Yamaguchi Shotai Kobayashi Ryoichi Takayanagi Toshio Ogihara Norihiro Kato | 2010 | Circulation2010，，21： | 1 |
| 13 | New tumor necrosis factor-α-inducing protein released from Helicobacter pylori for gastric cancer progression显示文摘 | Masami Suganuma Miki Kurusu Kaori Suzuki Akira Nishizono Kazunori Murakami Toshio Fujioka Hirota Fujiki | 2005 | Journal of Cancer Research and Clinical Oncology2005，，5： | 1 |
| 14 | Helicobacter pylori infection accelerates human gastric mucosal cell proliferation显示文摘 | Kazunari Murakami Toshio Fujioka Reiji Kodama Toshihiro Kubota Masashi Tokieda Masaru Nasu | 1997 | Journal of Gastroenterology1997，，2： | 1 |
| 15 | Association between Helicobacter pylori Virulence Factors and Gastroduodenal Diseases in Okinawa, Japan显示文摘 | Osamu Matsunari Seiji Shiota Rumiko Suzuki Masahide Watada Nagisa Kinjo Kazunari Murakami Toshio Fujioka Fukunori Kinjo Yoshio Yamaoka | 2012 | Journal of Clinical Microbiology2012，，7： | 1 |
| 16 | New tumor necrosis factor-α-inducing protein released from Helicobacter pylori for gastric cancer progression显示文摘 | Masami Suganuma Miki Kurusu Kaori Suzuki Akira Nishizono Kazunori Murakami Toshio Fujioka Hirota Fujiki | 2005 | Journal of Cancer Research and Clinical Oncology2005，，5： | 1 |
| 17 | Endoscopic closure of a large ERCP-related lateral duodenal perforation by using endoloops and endoclips显示文摘 | Yoshifumi Nakagawa Takayuki Nagai Wataru Soma Hitoshi Okawara Hiroshi Nakashima Takako Tasaki Akari Hisamatu Masahiko Hashinaga Kazunari Murakami Toshio Fujioka | 2010 | Gastrointestinal Endoscopy2010，，1： | 1 |
| 18 | The Incidence of Primary Antibiotic Resistance of Helicobacter pylori in Vietnam显示文摘 | Tran T. Binh Seiji Shiota Lam T. Nguyen Dung D.Q. Ho Hai H. Hoang Long Ta Dung T. Trinh Toshio Fujioka Yoshio Yamaoka | 2013 | Journal of Clinical Gastroenterology2013，，3： | 1 |
| 19 | Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects显示文摘 | Toshio Fujioka Aoi Yoshiiwa Tadayoshi Okimoto Masaaki Kodama Kazunari Murakami | 2007 | Journal of Gastroenterology2007，，17： | 1 |
| 20 | Association of Helicobacter pylori dupA With the Failure of Primary Eradication显示文摘 | Seiji Shiota Lam Tung Nguyen Kazunari Murakami Akiko Kuroda Kazuhiro Mizukami Tadayoshi Okimoto Masaaki Kodama Toshio Fujioka Yoshio Yamaoka | 2012 | Journal of Clinical Gastroenterology2012，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员